US Patent No: 7,977,316

Number of patents in Portfolio can not be more than 2000

Prevention and treatment of amyloidogenic diseases

ALSO PUBLISHED AS: 20080248023
1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ONCLAVE THERAPEUTICS LIMITEDDUBLIN, IE2

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Schenk, Dale B Pacifica, CA 156 3395

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
2002/0009,445 Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease 85 2001
2002/0197,258 Compositions and methods for preventing protein aggregation in neurodegenerative diseases 74 2002
 
NOVARTIS;CORPORATE INTELLECTUAL PROPERTY (1)
* 5,866,124 Antiidiotypic antibodies for high molecular weight-melanoma associated antigen 7 1996
 
RAMOT AT TEL-AVIV UNIVERSITY LTD. (1)
5,688,651 Prevention of protein aggregation 91 1994
 
Syntex (U.S.A.) Inc. (1)
5,208,036 N-(.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor 128 1990
 
ZOETIS WHC 2 LLC (1)
5,989,566 Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation 51 1996
 
GLAXOSMITHKLINE LLC (1)
5,854,204 A.beta. peptides that modulate .beta.-amyloid aggregation 103 1996
 
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (1)
2003/0147,882 METHODS FOR AMYLOID REMOVAL USING ANTI-AMYLOID ANTIBODIES 43 1999
 
Eli Lilly and Company (7)
5,441,870 Methods for monitoring cellular processing of .beta.-amyloid precursor protein 127 1992
5,612,486 Transgenic animals harboring APP allele having swedish mutation 135 1993
6,114,133 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41) 90 1994
5,593,846 Methods for the detection of soluble .beta.-amyloid peptide 205 1995
5,605,811 Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein 80 1995
5,837,672 Methods and compositions for the detection of soluble .beta.-amyloid peptide 107 1995
6,284,221 Method for identifying .beta.-amyloid peptide production inhibitors 72 1996
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (2)
5,750,349 Antibodies to .beta.-amyloids or their derivatives and use thereof 124 1994
5,955,317 Antibodies to .beta.-amyloids or their derivatives and use thereof 84 1997
 
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (2)
5,585,100 Dual carrier immunogenic construct 71 1995
5,955,079 Dual carrier immunogenic construct 59 1995
 
DMS PHARMACEUTICAL INC. (1)
5,231,170 Antibodies to dense microspheres 76 1990
 
AMYLIN PHARMACEUTICALS, INC. (1)
5,266,561 Treatment of type 2 diabetes mellitus 20 1991
 
BRONSON NUTRITIONALS, LLC (5)
5,869,093 Treatment of immune diseases by oral administration of autoantigens 63 1994
5,645,820 Treatment of autoimmune diseases by aerosol administration of autoantigens 60 1995
5,571,499 Treatment of autoimmune diseases by aerosol administration of autoantigens 75 1995
5,571,500 Treatment of autoimmune diseases through administration by inhalation of autoantigens 61 1995
5,641,474 Prevention of autoimmune diseases by aerosol administration of autoantigens 58 1995
 
SCIOS NOVA INC. (3)
5,220,013 DNA sequence useful for the detection of Alzheimer's disease 71 1989
5,187,153 Methods of treatment using Alzheimer's amyloid polypeptide derivatives 75 1990
5,387,742 Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease 189 1991
 
SUN HEALTH CORPORATION, INC. (1)
5,192,753 Anti-rheumatoid arthritic drugs in the treatment of dementia 86 1991
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (3)
4,666,829 Polypeptide marker for Alzheimer's disease and its use for diagnosis 258 1985
5,270,165 Method of diagnosis of amyloidoses 77 1991
5,750,361 Formation and use of prion protein (PRP) complexes 63 1995
 
AUTOIMMUNE, INC. (4)
5,849,298 Treatment of multiple sclerosis by oral administration of bovine myelin 49 1993
5,869,054 Treatment of multiple sclerosis by oral administration of autoantigens 54 1995
5,733,547 Treatment of autoimmune arthritis by oral administration of type I or type III collagen 52 1995
5,641,473 Treatment of autoimmune diseases by aerosol administration of autoantigens 52 1995
 
MILKHAUS LABORATORY, INC. (3)
5,753,624 Materials and methods for treatment of plaquing disease 82 1996
5,851,996 Materials and methods for treatment of plaquing diseases 88 1998
6,294,171 Methods for treating disease states comprising administration of low levels of antibodies 68 2001
 
Taurus International Manufacturing, Inc. (1)
5,972,269 Method of forming cavities in ceramic or metal injection molded parts using a fugitive core 14 1997
 
UNIVERSITY OF WASHINGTON (1)
5,958,883 Animal models of human amyloidoses 76 1995
 
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
6,417,178 Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits 74 1997
 
TEKTRONIX, INC. (1)
5,854,996 Logic signal extraction 28 1994
 
ANDRULIS PHARMACEUTICALS CORPORATION (1)
5,434,170 Method for treating neurocognitive disorders 88 1993
 
ABBVIE BIOTHERAPEUTICS INC. (1)
5,622,701 Cross-reacting monoclonal antibodies specific for E- and P-selectin 61 1994
 
ALZA CORPORATION (1)
5,972,369 Diffusional implantable delivery system 66 1998
 
BAYER PHARMACEUTICALS CORPORATION (1)
5,786,180 Monoclonal antibody 369.2B specific for .beta. A4 peptide 71 1995
 
ANTIGENICS INC. (2)
5,057,540 Saponin adjuvant 182 1990
5,583,112 Saponin-antigen conjugates and the use thereof 89 1992
 
EPIMMUNE INC. (1)
5,736,142 Alteration of immune response using pan DR-binding peptides 74 1994
 
The Scripps Research Institute (1)
5,846,533 Antibodies specific for native PrP.sup.Sc 76 1996
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
4,883,666 Controlled drug delivery system for treatment of neural disorders 211 1987
 
HUNTINGTON POTTER (1)
5,780,587 Compounds and methods for inhibiting .beta.-protein filament formation and neurotoxicity 76 1995
 
BHI LIMITED PARTNERSHIP (1)
5,643,562 Method for treating amyloidosis 38 1995
 
UNIVERSITY OF ROCHESTER (1)
5,231,000 Antibodies to A4 amyloid peptide 110 1991
 
MCW RESEARCH FOUNDATION, INC. (1)
6,057,367 Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses 79 1997
 
ALTEON, INC. (1)
5,935,927 Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts 75 1996
 
BOSTON BIOMEDICAL RESEARCH INSTITUTE (1)
2002/0136,718 Immunological control of beta-amyloid levels in vivo 61 2001
 
PROTEIN DESIGN LABS, INC. (1)
5,530,101 Humanized immunoglobulins 847 1990
 
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (1)
6,150,091 Direct molecular diagnosis of Friedreich ataxia 51 1996
 
PARDRIDGE, WILLIAM (1)
5,004,697 Cationized antibodies for delivery through the blood-brain barrier 88 1987
 
NEW YORK UNIVERSITY (1)
5,948,763 Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits 18 1996
 
CYTRX CORPORATION (1)
5,824,322 Compositions and methods for growth promotion 54 1996
 
SONORAN DESERT CHEMICALS LIMITED LIABILITY COMPANY (1)
* 5,290,762 Treatment of inflammation 22 1993
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (3)
5,837,473 Methods of screening for agents affecting the deposition of .beta.-amyloid peptides on amyloid plaques in human tissue 51 1995
5,877,399 Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease 118 1996
6,262,335 Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 54 1998
 
CEDARS-SINAI MEDICAL CENTER (1)
5,679,348 Immunotherapy for recurrent HSV infections 49 1992
 
NEOTOPE BIOSCIENCES LIMITED (1)
6,923,964 Active immunization of AScr for prion disorders 33 2000
 
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (1)
5,744,368 Methods for the detection of soluble amyloid .beta.-protein (.beta.AP) or soluble transthyretin (TTR) 61 1993
 
TRUSTEES OF BOSTON UNIVERSITY (1)
5,262,303 Ligand/anti-ligand assays for adherent proteins 7 1990
 
NATIONAL RESEARCH COUNCIL OF CANADA (1)
* 5,773,007 Vaccine compositions 27 1994
 
GLAXOSMITHKLINE BIOLOGICALS S.A. (1)
5,776,468 Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A 79 1996
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
BIOARCTIC NEUROSCIENCE AB (2)
8,859,501 Protofibril-binding antibodies and their use in thereapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies 0 2013
8,968,734 Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other α-synucleinopathies 0 2014
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jan 12, 2015
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 12, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 12, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00